Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
Jessica A. Couch(Sunesis (United States)), Ryan J. Watts(Denali Therapeutics (United States)), Kimberly Scearce‐Levie, Quyen Nguyen(Atotech (United States)), Mercedesz Balázs, Hilda Solanoy, Benjamin Ordonia(Atotech (United States)), James A. Ernst, William J. Meilandt, Wilman Luk(Genentech), Kwame Hoyte, Kapil Gadkar(Sea Turtle Conservancy), Mark S. Dennis(Denali Therapeutics (United States)), Yanmei Lu, Yin Zhang(Sun Yat-sen University), Raymond K. Tong, Yuwen Linda Lin(Atotech (United States)), Jacqueline M. Tarrant, Zhonghua Lin, Reina N. Fuji, Yang Yu(Obstetrics and Gynecology Hospital of Fudan University), Saileta Prabhu
Cited by 267
Related Papers
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
|Nature Biotechnology|2008|1.4k
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
|Nature Biotechnology|2012|997
Engaging neuroscience to advance translational research in brain barrier biology
|Nature reviews. Neuroscience|2011|586
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
|Science Translational Medicine|2015|541
Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins
|Journal of Biological Chemistry|2002|496